Literature DB >> 12119473

Expression of a functional asialoglycoprotein receptor in human renal proximal tubular epithelial cells.

Ying-ying T Seow1, Michelle G K Tan, Keng Thye Woo.   

Abstract

BACKGROUND: The asialoglycoprotein receptor (ASGPR) is a C lectin which binds and endocytoses serum glycoproteins. In humans, the ASGPR is shown mainly to occur in hepatocytes, but does occur extrahepatically in thyroid, in small and large intestines, and in the testis. In the kidney, there has been evidence both for and against its existence in mesangial cells.
METHODS: Standard light microscopy examination of renal tissue stained with an antibody against the ASGPR was performed. The mRNA expression for the ASGPR H1 and H2 subunits in primary human renal proximal tubular epithelial cells (RPTEC), in the human proximal tubular epithelial cell line HK2, and in human renal cortex was investigated using reverse-transcribed nested polymerase chain reaction. ASGPR protein expression as well as ligand binding and uptake were also examined using confocal microscopy and flow cytometry (fluorescence-activated cell sorting).
RESULTS: Light microscopy of paraffin renal biopsy sections stained with a polyclonal antibody against the ASGPR showed proximal tubular epithelial cell staining of the cytoplasm and particularly in the basolateral region. Renal cortex and RPTEC specifically have mRNA for both H1 and H2 subunits of the ASGPR, but HK2 only expresses mRNA for H1. Using a monoclonal antibody, the presence of the ASGPR in RPTEC was shown by fluorescence-activated cell sorting and immunofluorescent staining. Specific binding and uptake of fluorescein isothiocyanate labelled asialofetuin which is a specific ASGPR ligand was also demonstrated in RPTEC.
CONCLUSIONS: Primary renal proximal tubular epithelial cells have a functional ASGPR, consisting of the H1 and H2 subunits, that is capable of specific ligand binding and uptake. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12119473     DOI: 10.1159/000064283

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  5 in total

Review 1.  Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.

Authors:  Chaudry Nasir Majeed; Christopher D Ma; Ted Xiao; Sean Rudnick; Herbert L Bonkovsky
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

2.  Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha.

Authors:  Daniel Rycroft; Jane Sosabowski; Edward Coulstock; Marie Davies; John Morrey; Sarah Friel; Fiona Kelly; Robert Hamatake; Milan Ovečka; Rob Prince; Laura Goodall; Armin Sepp; Adam Walker
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

3.  Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis.

Authors:  Fatima Khaja; Dulari Jayawardena; Antonina Kuzmis; Hayat Önyüksel
Journal:  Nanomaterials (Basel)       Date:  2016-01-05       Impact factor: 5.076

Review 4.  The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies.

Authors:  Maja M Janas; Carole E Harbison; Victoria K Perry; Brenda Carito; Jessica E Sutherland; Akshay K Vaishnaw; Natalie D Keirstead; Garvin Warner
Journal:  Toxicol Pathol       Date:  2018-08-23       Impact factor: 1.902

5.  Liver-targeting of interferon-alpha with tissue-specific domain antibodies.

Authors:  Edward Coulstock; Jane Sosabowski; Milan Ovečka; Rob Prince; Laura Goodall; Clare Mudd; Armin Sepp; Marie Davies; Julie Foster; Jerome Burnet; Gráinne Dunlevy; Adam Walker
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.